News for Hims & Hers Health, Inc. (HIMS)

Stocks Analysis by MarketBeat.com (Jea Yu) covering: Eli Lilly and Company, Novo Nordisk A/S, Hims Hers Health Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

These three stocks tumbled by at least 20% last week, but they may not be down for long.

NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices (

Hims & Hers Health shuts down Apostrophe to streamline dermatology products. Read more here.

We recently compiled a list of the 10 Stocks Drop Double Digits as Investor Caution Lingers. In this article, we are going to take a look at where Hims & Hers Health, Inc.

Financial giants have made a conspicuous bullish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health HIMS revealed 21 unusual tra...

HIMS trading within one standard deviation of its 50-day moving average

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

U.S. markets suffered a steep selloff Monday as President Donald Trump announced sweeping new tariffs, extending last week's losses and driving declines across all major sectors.

We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this article, we are going to take a look at where Hims & Hers Health, Inc.

We recently compiled a list of the Wall Street Optimism Spills Over to These 10 Stocks on Friday. In this article, we are going to take a look at where Hims & Hers Health, Inc.

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) plummeted following its fourth-quarter earnings report. Hims & Hers has been selling semaglutide-based GLP-1 compound drugs under an FDA exception since the drug was in shortage. Let's take a closer look at Hims & Hers' most recent report and forecast, to determine whether the sell-off is a buying opportunity.

Investors with a lot of money to spend have taken a bullish stance on Hims & Hers Health HIMS. And retail traders should know. We noticed this today when the ...

In a recent appearance on CNBC's Squawk on the Street, Jim Cramer commented on a late-hours market selloff. Cramer shared that he was

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Stocks Analysis by MarketBeat.com (Leo Miller) covering: Hims Hers Health Inc, Nuscale Power Corp. Read MarketBeat.com (Leo Miller)'s latest article on Investing.com

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS stock is a Sell.

Hims & Hers Health targets the $4T US healthcare industry, boasting 95% y/y revenue growth & a Strong Buy rating. Click here for a post-earnings analysis.